Phase 2 pivotal registrational study of BCB-276
Latest Information Update: 14 Jan 2025
Price :
$35 *
At a glance
- Drugs BCB 276 (Primary)
- Indications Diffuse intrinsic pontine glioma
- Focus Registrational; Therapeutic Use
- 14 Jan 2025 New trial record
- 07 Jan 2025 According to BrainChild Bio media release, company look forward to the initiation of the BCB-276 pivotal trial by the end of 2025.
- 07 Jan 2025 According to BrainChild Bio media release, company plans to advance BCB-276 in a single pivotal registration trial designed to accelerate the path to submit a Biologics License Application for the treatment of children and young adults with DIPG. This clinical plan is based on alignment with the FDA at a Type B meeting. This potentially accelerated clinical path for BCB-276 is supported by the preliminary data for BCB-276 from a Phase 1 clinical trial conducted by Seattle Children.